Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 111 posts found.

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

March 20, 2024
Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …

News

Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment

February 26, 2024
Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide

Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …

News

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023
Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …

News

Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal

May 9, 2023
Research and Development Boehringer Ingelheim, Rare Diseases, cell programming, ginkgo bioworks, undruggable targets

German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks have announced a partnership to …

News
boehringer_biberach_germany_copy

Researchers and pharma companies partner to investigate new schizophrenia treatment

January 21, 2021
Biogen, Boehringer Ingelheim

The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …

News

Boehringer Ingelheim and Enara Bio to collaborate on cancer immunotherapies

January 12, 2021
Manufacturing and Production Boehringer Ingelheim, Cancer, Enara Bio

Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted …

News
boehringer_biberach_germany_copy

Boehringer’s nintedanib approved in Europe for systemic sclerosis-associated interstitial lung disease

April 22, 2020
Research and Development, Sales and Marketing Boehringer Ingelheim, EU, nintedanib, pharma

The European Commission has moved to authorise Boehringer Ingelheim’s nintedanib in Europe for the treatment of systemic sclerosis-associated interstitial lung …

News
jardiance-web

FDA advisory committee votes down approval of Boehringer and Lilly’s drug for type 1 diabetes

November 14, 2019
Sales and Marketing Boehringer Ingelheim, Eli Lilly, empagliflozin, jardiance, pharma

Boehringer Ingelheim and Eli Lilly’s have been dealt a blow from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), …

News
boehringer_biberach_germany_copy

Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease

September 10, 2019
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease

Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …

News
shutterstock_273326141

Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal

September 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma

Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …

News
headquarters_ingelheim3

Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population

August 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma

German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …

News
boehringer_biberach_germany_copy

Boehringer buys cancer vaccine company AMAL Therapeutics for €325 million

July 16, 2019
Manufacturing and Production AMAL Therapeutics, Boehringer Ingelheim, Geneva, cancer vaccines, oncology

Boehringer Ingelheim has bought Swiss biotech AMAL Therapeutics, a company focused on cancer immunotherapy and cancer vaccines. AMAL’s lead candidate, …

News

Boehringer Ingelheim open new plant in Catalonia

June 17, 2019
Sales and Marketing Boehringer Ingelheim, Catalonia, Sant Cugat de Valles, barcelona, pharma

Boehringer Ingelheim has opened a new manufacturing facility in the town of Sant Cugat del Vallès near Barcelona. The new …

News
simon-sturge-kymab-tile

Kymab announces Merck exec Simon Sturge as new CEO

April 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma

UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …

Appointment
bi_german_building_at_night

Boehringer expands manufacturing facility in Shanghai

January 22, 2019
Manufacturing and Production Boehringer Ingelheim, China, Shanghai, facilities, manufacturing, pharma

German firm Boehringer Ingelheim has expanded the capacity of its commercial manufacturing site for biologics in Shanghai, China. The expansion …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024